Literature DB >> 8640783

Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis.

H Gabra1, J E Watson, K J Taylor, J Mackay, R C Leonard, C M Steel, D J Porteous, J F Smyth.   

Abstract

Previous cytogenetic and loss of heterozygosity (LOH) data suggest that disruption of chromosome 11q23-qter occurs frequently in epithelial ovarian cancer and is associated with an adverse clinicopathological phenotype. Ten polymorphic microsatellite repeat loci were analyzed by PCR from the 11q22-q25 region between D11S35 and D11S968 in 40 ovarian tumors (including 31 epithelial ovarian cancers). Two distinct regions of loss were detected, suggesting possible sites for genes involved in epithelial ovarian neoplasia: a large centromeric region between D11S35 and D11S933 (11q22-q23.3) and a telomeric 8.5-Mb region lying between D11S934 and D11S1320 (11q23.3-24.3) not previously defined. LOH of the latter region but not the former one was significantly associated with poor survival, despite all tumors in this study having LOH somewhere on chromosome 11. This analysis provides a starting point for positional cloning.

Entities:  

Mesh:

Year:  1996        PMID: 8640783

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  The analysis of a large Danish family supports the presence of a susceptibility locus for adenoma and colorectal cancer on chromosome 11q24.

Authors:  Laura Aviaja Rudkjøbing; Hans Eiberg; Hanne Birte Mikkelsen; Marie Louise Mølgaard Binderup; Marie Luise Bisgaard
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

2.  Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors.

Authors:  Hugo Arias-Pulido; Harriet O Smith; Nancy E Joste; Therese Bocklage; Clifford R Qualls; Allison Chavez; Eric R Prossnitz; Claire F Verschraegen
Journal:  Gynecol Oncol       Date:  2009-06-27       Impact factor: 5.482

3.  Homeobox Gene Deregulation: Impact on the Hallmarks of Cancer.

Authors:  Dhwani Haria; Honami Naora
Journal:  Cancer Hallm       Date:  2013-09-01

Review 4.  Progesterone action in breast, uterine, and ovarian cancers.

Authors:  Caroline H Diep; Andrea R Daniel; Laura J Mauro; Todd P Knutson; Carol A Lange
Journal:  J Mol Endocrinol       Date:  2015-01-13       Impact factor: 5.098

5.  Localization of multiple melanoma tumor-suppressor genes on chromosome 11 by use of homozygosity mapping-of-deletions analysis.

Authors:  E K Goldberg; J M Glendening; Z Karanjawala; A Sridhar; G J Walker; N K Hayward; A J Rice; D Kurera; Y Tebha; J W Fountain
Journal:  Am J Hum Genet       Date:  2000-07-29       Impact factor: 11.025

6.  Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming.

Authors:  Caroline H Diep; Todd P Knutson; Carol A Lange
Journal:  Mol Cancer Res       Date:  2015-11-17       Impact factor: 5.852

7.  Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells.

Authors:  K M Lau; S C Mok; S M Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

8.  An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Kozue Suzuki; Masashi Takano; Seiichi Tamai; Osamu Matsubara
Journal:  Virchows Arch       Date:  2009-08-05       Impact factor: 4.064

Review 9.  Multiple roles of CD90 in cancer.

Authors:  Atul Kumar; Anshuman Bhanja; Jina Bhattacharyya; Bithiah Grace Jaganathan
Journal:  Tumour Biol       Date:  2016-06-23

10.  LARG at chromosome 11q23 has functional characteristics of a tumor suppressor in human breast and colorectal cancer.

Authors:  D C T Ong; Y M Ho; C Rudduck; K Chin; W-L Kuo; D K H Lie; C L M Chua; P H Tan; K W Eu; F Seow-Choen; C Y Wong; G S Hong; J W Gray; A S G Lee
Journal:  Oncogene       Date:  2009-09-07       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.